“Can cataracts be treated without surgery?” It is a question many patients ask, especially when their vision is starting to change but they are not ready for an operation. The possibility of an eye drop that could slow cataract formation—or someday improve the clarity of a cloudy lens—is understandably exciting.
Scientists are studying several approaches, including lanosterol, specially designed sterol molecules, antioxidant compounds, and an EDTA-based eye drop. Some have shown encouraging results in laboratory or animal studies, while others have advanced to human clinical trials. Although no medication has yet been proven and approved to remove an established cataract, the research is moving beyond theory and into more meaningful clinical testing.
What Happens Inside the Lens When a Cataract Forms?
The natural lens, located behind the iris, focuses light so we can see clearly. Its transparency depends on a precise arrangement of proteins called crystallins. Over time, aging, oxidative stress, and other changes can cause these proteins to become damaged, lose their orderly structure, and aggregate. The resulting cloudiness scatters light and may cause blurry vision, glare, faded colors, or difficulty seeing at night.
Cataracts do not develop in exactly the same way for everyone. Age, diabetes, smoking, ultraviolet light exposure, previous eye injury, and prolonged corticosteroid use can influence when cataracts appear and how quickly they progress. Researchers hope that understanding these different pathways will eventually lead to treatments tailored to the type and stage of cataract.
Can You Reduce Your Risk of Developing Cataracts?
While cataracts are a common part of aging and cannot always be prevented, several steps may help protect long-term eye health. Wear sunglasses that block UVA and UVB rays and a brimmed hat outdoors. Avoid smoking, use protective eyewear when appropriate, and manage diabetes and other chronic medical conditions. A varied diet that includes leafy greens, colorful fruits and vegetables, nuts, and other nutrient-rich foods supports overall health.
Antioxidants such as vitamins C and E, lutein, and zeaxanthin have attracted interest because oxidative stress contributes to lens aging. However, studies have not established that taking high-dose vitamin supplements routinely prevents cataracts or reverses existing lens cloudiness. Healthy habits may help reduce risk, but they do not replace regular eye examinations.
Lanosterol: The Discovery That Opened the Door
Lanosterol is a naturally occurring molecule involved in cholesterol synthesis and found in the lens. A widely discussed 2015 study reported that lanosterol reduced abnormal crystallin-protein aggregation in laboratory experiments and improved lens clarity in certain rabbit-lens and dog models of cataract. This raised a remarkable possibility: perhaps a future medication could target the protein changes underlying cataracts, rather than requiring the cloudy lens to be removed.
The science has not been uniform. Other investigators were unable to reproduce the same improvements in some lens experiments, including studies involving human lens material. Lanosterol also has practical drug-delivery limitations: it does not dissolve readily in water, and getting enough of a compound through the eye and into the lens is challenging. These findings do not establish lanosterol drops as a cataract treatment for people, but they have inspired important work on newer molecules and formulations.
New Lanosterol Derivatives: C6 and C34
One way to build on the lanosterol discovery is to modify the molecule itself. Researchers have synthesized lanosterol derivatives, including compounds referred to as C6 and C34, to improve properties such as solubility and activity against abnormal lens-protein aggregation.
In laboratory and cell-based research, some of these derivatives performed better than unmodified lanosterol in experimental systems involving crystallin proteins. This is an encouraging step in drug design, because a compound must be both biologically active and capable of reaching its target in the eye. However, C6 and C34 remain early research compounds: their ability to prevent or reverse age-related cataracts in human patients has not been established.
VP1-001 (Compound 29): An Oxysterol Being Studied for Lens Clarity
Another promising research molecule is VP1-001, also known as compound 29 or 25-hydroxycholesterol. It belongs to a group of cholesterol-related molecules called oxysterols. Researchers have explored whether VP1-001 can act as a “pharmacologic chaperone,” helping stabilize alpha-crystallin proteins that contribute to maintaining lens transparency.
In a 2022 mouse study, topical VP1-001 improved the measured refractive-index profile of 61% of the studied lenses and reduced apparent lens opacity scores in 46% of live animals. Related experiments found improvements in lens clarity in some mouse models. These results are notable because researchers looked not only at the appearance of the cataract but also at how the lens focuses light.
At the same time, other laboratory studies have reported less encouraging findings with oxysterols. VP1-001 has not demonstrated that it can reliably restore vision in people with age-related cataracts. It remains a preclinical area of investigation rather than an available cataract medication.
ZOC2017217: A Lanosterol-Related Eye Drop in Human Trials
An especially interesting development is ZOC2017217, a lanosterol-derived investigational eye drop that has entered human clinical testing for age-related cataracts. A U.S. randomized, double-masked, placebo-controlled Phase 2 pilot study began in 2026, with approximately 40 participants expected to use study drops for 24 weeks.
Researchers are studying safety alongside measures that matter to everyday vision, including visual acuity, contrast sensitivity, and changes in lens cloudiness. In July 2026, the study team announced enrollment of its first U.S. participant. The pilot study is intended to inform possible larger Phase 3 research.
ZOC2017217 is an important example of the field progressing from the laboratory toward patient-centered testing. However, the ongoing trial has not yet established that the drops can reverse cataracts or safely delay surgery. It is not an FDA-approved cataract treatment.
C-KAD: An EDTA-Based Eye Drop With Encouraging Human Results
C-KAD, developed by Livionex, takes a different approach. Instead of using a sterol, it contains a specially formulated 2.6% solution of ethylenediaminetetraacetic acid (EDTA), a compound that binds certain metal ions. Researchers are investigating whether this approach can influence biochemical processes that contribute to early lens clouding and improve visual quality.
A published subgroup analysis of a randomized Phase 1/2 study evaluated 41 eyes with early cataracts and reduced contrast sensitivity. After 120 days, approximately 67% of C-KAD-treated eyes achieved a predefined improvement in low-light contrast sensitivity, compared with 35% of placebo-treated eyes. Researchers also reported favorable findings in some measures of lens density.
These findings are encouraging because many people notice difficulty with night driving, glare, or low-contrast objects before their standard eye-chart vision declines significantly. Nevertheless, the published findings came from a small subgroup analysis, and larger confirmatory trials are needed. The developer has reported plans to advance C-KAD into Phase 3 testing; it is not yet FDA-approved for cataract treatment.
Antioxidant Drops: N-Acetylcysteine Amide (NACA) and N-Acetylcarnosine
Oxidative stress is another major focus of cataract research. Investigators are studying compounds that may help preserve the lens’s antioxidant defenses and protect crystallin proteins from oxidative damage. Two names often mentioned are N-acetylcysteine amide and N-acetylcarnosine. Although their names sound similar, these are different molecules.
N-acetylcysteine amide (NACA) is a modified antioxidant compound designed to enter cells more readily than conventional N-acetylcysteine. In animal studies, including experiments using cataract-producing oxidative stress in rats, NACA reduced cataract formation or severity, and topical NACA produced favorable results in some models. These findings support further investigation, but human clinical benefit for age-related cataracts has not been demonstrated.
N-acetylcarnosine is a related-sounding but distinct compound that has also been studied as an antioxidant eye drop. Small earlier human studies reported improvements in some measures of vision, glare, or lens clarity. However, a Cochrane review could not verify the studies well enough to draw reliable conclusions and found no convincing evidence that N-acetylcarnosine prevents or reverses cataracts. Drops containing this ingredient may be marketed to consumers, but they are not FDA-approved to treat or reverse cataracts.
The broader concept remains scientifically interesting: if future treatments can protect lens proteins before significant clouding develops, they may be especially useful in early cataracts. For now, these compounds should be understood as research candidates, not proven alternatives to surgery.
If You Have a Cataract Now, Must You Have Surgery Right Away?
Not necessarily. Early cataracts can often be monitored safely when vision remains adequate for daily activities. An updated glasses prescription, brighter lighting, glare reduction, and treatment of coexisting dry eye may improve comfort and day-to-day function without changing the cataract itself.
Your ophthalmologist can help assess whether a cataract is actually responsible for your symptoms and whether it is affecting activities such as reading, working, or driving. If the cataract is significantly limiting vision, surgery remains the only established method of removing the cloudy natural lens. Delaying needed treatment in the hope that investigational drops will become available is not appropriate for every patient.
Why the Right Approach Is Different for Every Patient
A mild nuclear cataract in one patient may behave differently from a posterior subcapsular cataract, a dense cortical cataract, or a cataract associated with diabetes or medication use. Some patients also have glaucoma, macular degeneration, or another condition that affects their vision. These differences matter when deciding whether to monitor, treat accompanying conditions, or consider surgery.
Patients deserve to learn about emerging research without being promised results the science has not yet established. As clinical trials develop, a future nonsurgical treatment may prove useful for certain types or stages of cataract rather than for everyone. A comprehensive eye examination remains the best way to understand the options appropriate for you.
The Bottom Line
Research on nonsurgical cataract treatment is advancing along several promising paths. Lanosterol launched interest in restoring lens transparency; derivatives such as C6 and C34 and the oxysterol VP1-001 have shown encouraging laboratory or animal findings; and antioxidant compounds such as NACA and N-acetylcarnosine continue to be studied. Most importantly, ZOC2017217 is in Phase 2 human testing, while C-KAD has reported encouraging early human results and is being prepared for larger confirmatory trials.
None of these eye drops is currently an FDA-approved substitute for cataract surgery. In the meantime, protecting your eyes, managing modifiable risk factors, and monitoring lens changes remain valuable. At Bohonos Eye Care, our goal is to help each patient understand both today’s proven treatment choices and the new possibilities that may shape cataract care in the years ahead.